Hudson M - Search Results

1

Adverse events associated with immune checkpoint inhibitor treatment for cancer.

Esfahani K, Meti N, Miller WH Jr, Hudson M. Esfahani K, et al. Among authors: hudson m. CMAJ. 2019 Jan 14;191(2):E40-E46. doi: 10.1503/cmaj.180870. CMAJ. 2019. PMID: 30642824 Free PMC article. Review. No abstract available.

2

Jamal S, Hudson M, Fifi-Mah A, Ye C. Jamal S, et al. Among authors: hudson m. J Rheumatol. 2020 Feb;47(2):166-175. doi: 10.3899/jrheum.190084. Epub 2019 Jul 15. J Rheumatol. 2020. PMID: 31308203 Free article. Review.

3

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation.

Esfahani K, Al-Aubodah TA, Thebault P, Lapointe R, Hudson M, Johnson NA, Baran D, Bhulaiga N, Takano T, Cailhier JF, Piccirillo CA, Miller WH. Esfahani K, et al. Among authors: hudson m. Nat Commun. 2019 Oct 17;10(1):4712. doi: 10.1038/s41467-019-12628-1. Nat Commun. 2019. PMID: 31624262 Free PMC article.

4

Moving towards personalized treatments of immune-related adverse events.

Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Esfahani K, et al. Among authors: hudson m. Nat Rev Clin Oncol. 2020 Aug;17(8):504-515. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3. Nat Rev Clin Oncol. 2020. PMID: 32246128 Review.

5

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.

Esfahani K, Hudson M, Batist G. Esfahani K, et al. Among authors: hudson m. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527. N Engl J Med. 2020. PMID: 32521140 No abstract available.

6

Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.

Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, Fifi-Mah A, Maltez N, Jamal S. Roberts J, et al. Among authors: hudson m. Autoimmun Rev. 2020 Aug;19(8):102595. doi: 10.1016/j.autrev.2020.102595. Epub 2020 Jun 11. Autoimmun Rev. 2020. PMID: 32535092 Review.

7

A New Era: Immunotherapy Applied to Contemporary Cardiovascular Practice.

Filimon S, Pop C, Chetrit M, Esfahani K, Hudson M, Rouleau J, Thanassoulis G, O'Meara E, Bouabdallaoui N, Michel C, Aziz H, Gold P, Tardif JC, Huynh T. Filimon S, et al. Among authors: hudson m. Can J Cardiol. 2022 Oct;38(10):1629-1633. doi: 10.1016/j.cjca.2022.05.013. Epub 2022 May 19. Can J Cardiol. 2022. PMID: 35598801 No abstract available.

8

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.

Tonneau M, Nolin-Lapalme A, Kazandjian S, Auclin E, Panasci J, Benlaifaoui M, Ponce M, Al-Saleh A, Belkaid W, Naimi S, Mihalcioiu C, Watson I, Bouin M, Miller W, Hudson M, Wong MK, Pezo RC, Turcotte S, Bélanger K, Jamal R, Oster P, Velin D, Richard C, Messaoudene M, Elkrief A, Routy B. Tonneau M, et al. Among authors: hudson m. Oncoimmunology. 2022 Jul 7;11(1):2096535. doi: 10.1080/2162402X.2022.2096535. eCollection 2022. Oncoimmunology. 2022. PMID: 35832043 Free PMC article.

9

A case of severe Pembrolizumab-induced neutropenia.

Barbacki A, Maliha PG, Hudson M, Small D. Barbacki A, et al. Among authors: hudson m. Anticancer Drugs. 2018 Sep;29(8):817-819. doi: 10.1097/CAD.0000000000000661. Anticancer Drugs. 2018. PMID: 29889673

10

Letter in response to 'Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors'.

Leclair V, Landon-Cardinal O, Hudson M. Leclair V, et al. Among authors: hudson m. Eur J Cancer. 2019 May;112:47-48. doi: 10.1016/j.ejca.2019.02.010. Epub 2019 Mar 23. Eur J Cancer. 2019. PMID: 30913530 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,358 results

Search Page